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The worldwide emergence of antibiotic resistance poses a serious threat to human health. A
molecular understanding of resistance strategies employed by bacteria is obligatory to
generate less-susceptible antibiotics. Albicidin is a highly potent antibacterial compound
synthesized by the plant-pathogenic bacterium Xanthomonas albilineans. The drug-binding
protein AlbA confers albicidin resistance to Klebsiella oxytoca. Here we show that AlbA binds
albicidin with low nanomolar afﬁnity resulting in full inhibition of its antibacterial activity. We
report on the crystal structure of the drug-binding domain of AlbA (AlbAS) in complex with
albicidin. Both α-helical repeat domains of AlbAS are required to cooperatively clamp albi-
cidin, which is unusual for drug-binding proteins of the MerR family. Structure-guided NMR
binding studies employing synthetic albicidin derivatives give valuable information about
ligand promiscuity of AlbAS. Our ﬁndings thus expand the general understanding of antibiotic
resistance mechanisms and support current drug-design efforts directed at more effective
albicidin analogs.
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The increasing number of antibiotic-resistant bacteriaworldwide has become a major public health threat. Dis-covery and study of different bacterial resistance strategies
as well as the development of new antimicrobial compounds,
which are also able to overcome the protecting outer-membrane
barrier of Gram-negative bacteria, are of great urgency1. Albicidin
is a phytotoxic small molecule synthesized by the Gram-negative
plant pathogen Xanthomonas albilineans that causes leaf scald
disease in sugarcane plants2. Besides its phytotoxicity, albicidin is
bactericidal in the nanomolar range against Gram-positive and in
particular against Gram-negative bacteria with low minimal
inhibitory concentrations (MIC), e.g., against Staphylococcus
aureus (4.0 μg mL−1), Salmonella enteritidis (0.5 μg mL−1),
Pseudomonas aeruginosa DSM 117 (1.0 μg mL−1), and Escher-
ichia coli (0.063 μg mL−1)3,4. The molecular target of albicidin is
DNA gyrase (topoisomerase II), an enzyme essential for bacterial
DNA replication. Albicidin has been reported to block the ATP-
dependent DNA cleavage-religation step at the gyrase A subunit3.
The biosynthesis of albicidin is based on a hybrid polyketide
synthase/nonribosomal peptide synthetase5,6. The structure of
albicidin consists of six building blocks (Fig. 1a): methyl p-cou-
maric acid (MCA-1) at the N terminus; two p-aminobenzoic
acids (pABA-2 and pABA-4); the unusual non-proteinogenic α-
amino acid β-cyano-L-alanine (L-Cya-3) centered in the structure;
and two 4-amino-2-hydroxy-3-methoxybenzoic acids (pMBA-5
and pMBA-6) at the C-terminal end. The structure elucidation5,7
of albicidin and a total synthesis route4 enabled initial structure-
activity relationship (SAR) studies8–10.
Previously, a number of resistance mechanisms against albicidin
have been described: examples include the nucleoside transporter
Tsx, for which mutations have been reported that compromise its
abilities to import albicidin11,12, or the endopeptidase AlbD from
Pantoea dispersa13, which cleaves albicidin into two inactive
fragments14. Another strategy that counteracts the antibacterial
effect of albicidin is drug binding, as it is also known for the
tetracycline-binding protein (TetR family)15 or the thiostrepton-
binding protein (MerR family)16. Examples of such albicidin-
binding proteins are AlbA from Klebsiella oxytoca17 and AlbB
from Alcaligenes denitriﬁcans18, which exert protective effects for
survival of the host strains. Previous studies on AlbA/AlbB have
demonstrated non-covalent binding of albicidin17,18. Furthermore,
far-ultraviolet (UV) circular dichroism (CD) spectroscopy has
indicated a mostly α-helical structure for AlbA19. Speciﬁc amino-
acid residues such as His125 have been suggested to play a role in
albicidin binding19,20. Due to high similarities to the DNA-binding
domains of transcriptional regulator proteins NifA and NtrC
(nitrogen regulatory protein) a classiﬁcation of AlbA/AlbB as
transcription activator proteins has been suggested19.
Transcriptional regulator proteins are widespread in nature.
For instance, the MerR (Mercury Resistance) transcriptional
regulator family is known to activate several multi-drug resistance
(MDR) systems in response to environmental stress21. Members
of this family are characterized by a highly conserved N-terminal
winged helix-turn-helix (HTH) DNA-binding motif. The HTH
motif is connected by a long coiled-coil linker to a C-terminal
effector-binding domain that differs in structure and function
among the family members21. Activation of these regulators
occurs in response to oxidative stress and heavy metals or small
molecules, e.g., antibiotics, binding to the effector domain22.
Well-known members of the MerR family are the transcriptional
regulators BmrR from Bacillus subtilis22,23, and SoxR from
Escherichia coli24. Another prominent and well-described MerR
system is the thiopeptide-binding protein TipA (thiostrepton-
induced protein A) from Streptomyces lividans25,26. The tipA gene
encodes for two alternate in-frame translation products: the long
form TipAL consisting of the N-terminal HTH DNA-binding
domain (TipAN), and the shorter C-terminal thiopeptide drug-
binding domain (TipAS)27. Drug binding to TipAL leads to an
upregulation of its own expression and confers resistance against
several thiopeptide antibiotics, e.g., thiostrepton, nosiheptide, and
promothiocin A16. Previously, Grzesiek and co-workers have
solved the solution structure of TipAS bound to various
thiopeptides16,27, which for the ﬁrst time gave insights into
binding determinants and domain dynamics of the protein.
In this work, we characterized the MerR-like drug-binding
protein AlbA that displays a high binding afﬁnity to albicidin. We
elucidated the crystal structure of the complex between albicidin
and the drug-binding domain AlbAS, demonstrating that this
domain is structurally distinct from other drug-binding domains
of MerR family members, such as BmrR23 or TipAS27. The
unusual topology of AlbAS comprises two tandem domains that
are required to wrap around and fully enclose the drug in the core
of the protein. Nuclear magnetic resonance (NMR), CD, and
ﬂuorescence spectroscopic measurements provided detailed
insights into the binding mechanism and the structural elements
required for drug binding of AlbA. Consistent with our structural
data, binding studies on synthetic albicidin derivatives revealed
ligand promiscuity of AlbAS for aromatic acylpentapeptides as
well as further supported our model of the binding mechanism.
Our ﬁndings represent valuable knowledge about antibiotic cap-
ture as an important resistance mechanism and how to possibly
circumvent it in the case of albicidin.
Results
AlbA is a MerR-like transcriptional regulator. A sequence
similarity search using Basic Local Alignment Search Tool
(BLAST) for AlbA (accession number (AC): Q8KRS7)17 and
AlbB (AC: Q44567)18 suggests that they belong to the MerR
family of transcriptional regulators (E-values of 10−160 (AlbA)
and 10−37 (AlbB)). Moreover, AlbA shows high structural
homology to the thiopeptide-binding protein TipAS (Supple-
mentary Figure 1). Further homologous proteins were identiﬁed
in various Gram-negative bacteria belonging to the family of
Enterobacteriaceae like Raoultella ornithinolytica, Leclercia ade-
carboxylata, or Enterobacter mori (Supplementary Figure 2A and
Supplementary Figure 3). Bioinformatic comparison of AlbA and
AlbB showed that while being distantly related in primary
structure, both proteins most probably share high secondary
structure similarity (Supplementary Figure 2B). A striking dif-
ference between both proteins is the isoelectric point (AlbA: pI=
4.99, AlbB: pI= 10.15) due to the reversed content of acidic (15%
for AlbA versus 8% for AlbB) and basic amino-acid residues (10%
for AlbA versus 15% for AlbB).
Bioinformatic analysis of the K. oxytoca and A. denitriﬁcans
genomes revealed a putative HTH motif in AlbA and AlbB that
might be involved in DNA binding. This domain is conserved in
several MerR-transcription activators21. In analogy to the TipA
system27, we assumed that the albA/albB genes each encode for
two proteins: a full-length protein and a truncated protein as a
result of two in-frame translation products. Based on the TipA
nomenclature27, we termed the full-length versions AlbAL/AlbBL
(AlbAL 40 kDa, 348 amino acids, AC: WP_016808841). Hence,
AlbAL/AlbBL consist of the MerR-characteristic N-terminal
HTH DNA-binding domain and the C-terminal drug-binding
domain AlbAS/AlbBS. Sequence alignments with TipAL and
secondary structure prediction illustrated that AlbAS (25.8 kDa,
221 amino acids) may comprise an unusual tandem arrangement
of two TipAS-like drug-binding domains (Supplementary Fig-
ure 1). Interested in the capture mechanism toward albicidin, we
subsequently focused on AlbAS and validated the results by
employing AlbAL in key experiments (Supplementary Figure 4A).
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AlbA captures albicidin with low nanomolar binding afﬁnity.
Initial in vitro agar diffusion assays with E. coli and a pre-
incubated AlbA-albicidin mixture clearly demonstrated the
albicidin-neutralizing effect of both AlbAS (Fig. 2a) and AlbAL
(Supplementary Figure 5A).
MIC values for albicidin were determined against four K.
oxytoca and seven Klebsiella pneumoniae strains as well as several
ESKAPE organisms such as P. aeruginosa, R. ornithinolytica,
Acinetobacter baumanii, and Enterobacter cloacae. All strains
were resistant against albicidin with MIC values of ≥64 µg mL−1.
By bioinformatic analysis, we identiﬁed AlbA homologs in many
of these pathogens (Supplementary Figure 3) indicating that AlbA
may function as a widespread resistance mechanism.
Far-UV CD spectroscopy of AlbAS and AlbAL in the absence
and presence of albicidin showed signal minima at wavelengths of
209 and 222 nm, which are characteristic of α-helical secondary
structures (Fig. 3a and Supplementary Figure 5B). No signiﬁcant
changes in secondary structure were induced by albicidin binding
to both proteins. However, assessing the thermodynamic protein
stabilities showed that the melting temperature, Tm, of AlbAS
increased signiﬁcantly upon albicidin binding from 66 to 81 °C
(Fig. 3b). Binding of albicidin to AlbAL caused a less-pronounced
increase in Tm from 71 to 74 °C (Supplementary Figure 5C).
We further inspected the structural rearrangement of AlbAS
upon albicidin binding via two-dimensional (2D) NMR experi-
ments with 15N-labeled AlbAS. The 1H-15N heteronuclear single-
quantum coherence (HSQC) spectrum of AlbAS was character-
ized by considerable line-broadening and signal overlap (Fig. 3e).
Peak picking yielded only 95 of the expected 209 cross-peaks. By
contrast, addition of albicidin not only caused chemical shift
changes but also the appearance of new cross-peaks (approxi-
mately 175 cross-peaks in total). For example, the well-resolved
indole region of tryptophans showed three versus nine cross-
peaks in the absence and presence of the ligand, respectively. A
tentative assignment of these side-chain signals using Trp-to-Phe
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a
Fig. 1 Structure of albicidin. a Albicidin is composed of six building blocks (denoted A–F): p-coumaric acid (MCA-1); p-aminobenzoic acid (pABA-2 and
pABA-4); non-proteinogenic α-amino acid L-Cya-3; and two 4-amino-2-hydroxy-3-methoxybenzoic acids (pMBA-5 and pMBA-6). b Overview of tested
compounds. Structural variations with respect to albicidin are highlighted in gray
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became detectable upon albicidin binding (Supplementary
Figure 6). Interestingly, the observation of doubled resonances
for the side chains of W56 and W133 indicated that these residues
adopt two different and slowly interconverting conformations in
the albicidin–AlbAS complex (Supplementary Figure 6). The
NMR data suggest that the extensive line-broadening for the
unbound AlbAS is caused by internal dynamics on a microsecond
to millisecond timescale, which are frozen in a more rigid
albicidin-bound state.
Size-exclusion chromatography with multi-angle light scatter-
ing (SEC-MALS) measurements yielded molecular masses, M, of
27.1 and 27.2 kDa for AlbAS in the absence and presence of
albicidin, respectively (Supplementary Figure 7A). In contrast to
monomeric AlbAS, the full-length protein AlbAL formed a dimer
in solution in both the unbound state (M of 82.2 kDa) and
albicidin-bound state (M of 85.5 kDa) (Supplementary Figure 7B).
Dimerization has been shown for other MerR proteins as well,
enabling DNA promoter binding28,21. In agreement with a
dimeric state, 2H,15N-labeled AlbAL yielded rather broad
resonance lines in 1H-15N transverse relaxation-optimized
spectroscopy (TROSY) experiments. More importantly, albicidin
binding to AlbAL caused many of the characteristic chemical shift
perturbations observed for AlbAS–albicidin indicating a very
similar binding mode (Supplementary Figure 5D and E).
In order to estimate the binding strength between AlbAS and
albicidin, we monitored characteristic signals in a well-resolved
reporter region of the 1H-15N HSQC spectrum during a titration
series (Supplementary Figure 8A). The simultaneous observation
of signals arising from both AlbAS and its albicidin-bound state,
as well as and the mutual change in populations of these two
states indicated a slow-exchange regime in agreement with strong
ligand binding in the nM–pM range (Supplementary Figure 8B
and Supplementary Figure 8C)29. Owing to this very strong
interaction and the high protein concentrations required in the
NMR experiments, we employed ﬂuorescence spectroscopy to
avoid ligand depletion effects and to ultimately determine the
dissociation constant, Kd, of albicidin binding to AlbAS and
AlbAL. The experimental read-out was based on quenching of
ﬂuorescence emission of AlbAS/AlbAL upon binding of albicidin
(Fig. 4a). Analysis of the observed binding response for AlbAS
yielded a Kd of 5.6 ± 0.2 nM and indicated positive cooperativity
with a Hill coefﬁcient, n, of 3.0 ± 0.5 (Fig. 4b). The full-length
protein AlbAL showed a similar binding afﬁnity (Kd of 7.4 ± 0.9
nM) and cooperativity (n of 2.0 ± 0.2) (Supplementary Figure 5F).
These results demonstrated that the drug-binding domain of
AlbA acts as a high-afﬁnity capture system for albicidin.
It has been shown previously that albicidin exhibits a half
maximal inhibitory concentration (IC50) of 40 nM for its
molecular target DNA gyrase3. To investigate whether AlbAS is
capable of protecting DNA gyrase against albicidin, we performed
an NMR-based in vitro competition experiment employing the
gyrase construct GyrBA59 from E. coli (Supplementary Fig-
ure 9A). Puriﬁed and enzymatically active GyrBA59 (Supple-
mentary Figure 9B and C) was incubated with MgCl2, ATP,
supercoiled pBR322 plasmid DNA, and equimolar amounts of
AlbAS. An equimolar amount of albicidin was then added to the
mixture to allow for direct competition. The overlay of 1H-15N
correlation spectra showed that AlbAS fully populated the
albicidin-bound state with no free AlbAS being detectable
(Supplementary Figure 9D and E). This demonstrated that AlbAS
can efﬁciently sequester albicidin before the inhibitor targets
DNA gyrase.
The structure of the AlbAS–albicidin complex. We obtained
well-diffracting crystals for the AlbAS–albicidin complex and
solved its structure by single-wavelength anomalous dispersion
with selenomethionine-labeled AlbAS (Fig. 5a). Model reﬁnement
(1.7 Å resolution) converged with excellent statistics and geo-
metry (Supplementary Table 1 and Supplementary Figure 10A
and B). The structure of AlbAS could be fully modeled except for
the C-terminal residues 215–221. An asymmetric unit contains
two copies of the protein that are virtually identical with a root
mean square deviation (rmsd) of 0.6 Å for all Cα atoms. AlbAS
adopts an all-α-helical fold in agreement with CD spectroscopy
(Fig. 3a). As postulated from our bioinformatic analysis (Sup-
plementary Figure 11A and Supplementary Figure 1), the struc-
ture of AlbAS is organized in two repeat units, i.e., the N-terminal
domain (NTD, residues M1-R112) and the C-terminal domain
(CTD, residues Y113-E221). A 24-residue α-helix (P92-R112)
connects the NTD with the CTD. To reﬂect the tandem
arrangement in AlbAS, we designated helices of the NTD as α1-
α6 and the equivalent helices of the CTD as α1′-α6′ (Supple-
mentary Figure 11A). The NTD and CTD are arranged relative to
each other via 21 screw pseudosymmetry and can be super-
imposed (using boundaries D20-L114 and D128-A215) with an
rmsd of 1.7 Å (Fig. 5b and Supplementary Figure 11A).
A DALI30 search for structurally related folds resulted in very
low Z-scores. The most related structure with a Z-score of 5.8 is
the drug-binding domain TipAS (PDB 2MBZ, in complex with
promothiocin A)27 with a sequence identity of only 13%. TipAS
(G111-P253) superimposes with both the NTD (M1-R112) and
CTD (Y113-Q214) of AlbAS with Cα rmsd values of 2.2 and 5.0
Å, respectively. The deviations mainly arise from structural
differences at the N-terminal regions, whereas helices α2-α6 of
the NTD (D20-L114) and helices α2′-α6′ of the CTD (Y128-
A215) can be well aligned to helices α9-α13 of TipAS (Y155-
P253) yielding rmsd values of 2.5 and 2.8 Å, respectively.
To test the albicidin-binding potential of the individual
domains, we prepared constructs comprising either the NTD
(AlbASNTD) or the CTD (AlbASCTD) (Supplementary Figure 4B).







AlbASNTD+ albicidin AlbASCTD+ albicidin AlbASM+ albicidin
Fig. 2 Agar diffusion assays. a–c AlbAS, AlbASNTD, AlbASCTD, and AlbASM (40 µM) with 40 μM albicidin (in triplicates I–III). The ﬁrst plate illustrates the
sample arrangement on the assay plates. Positive control with only 40 µM albicidin (+) and negative control with 40 µM protein in 5% DMSO and buffer
(−) are shown on top. Representative results are shown for three independent experiments
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1H-15N HSQC spectra (Supplementary Figure 12A and B).
However, in agar diffusion assays they failed to suppress the
antibacterial effects of albicidin (Fig. 2b). This observation can be
ascribed to diminished afﬁnities toward albicidin, as ﬂuorescence
spectroscopy yielded Kd values of 3.4 ± 0.2 μM (AlbASNTD) and
0.6 ± 0.1 μM (AlbASCTD), respectively (Fig. 4c).
In contrast to TipAS, which binds its macrocyclic ligands in an
N-terminal pocket (Fig. 5c)27, the elongated and rather rigid
albicidin molecule is accommodated in a central tunnel of AlbAS
thereby pervading both, its NTD and CTD. Interestingly, both
repeat units utilize an equivalent pocket to harbor the different
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Fig. 3 Impact of albicidin binding on structure and stability of AlbAS. a Far-UV CD spectra of AlbAS in the absence (black) or presence (red) of albicidin
(molar ratio 1.5:1 albicidin:AlbAS) at 21 °C. b–d CD-detected thermal unfolding of AlbAS in the absence (black) or presence (red) of albicidin, compound 5,
or compound 7. Tm values are indicated by dashed lines. For the overlay, the [Θ]MRW(215 nm) signals of AlbAS–albicidin and AlbAS–compound 5 were scaled
to that of AlbAS alone using a factor of 1.157 and 1.091, respectively. e–g Overlay of 1H-15N HSQC NMR spectra of AlbAS in the absence (black) or
presence (red) of albicidin, compound 5, or compound 7, respectively. CD experiments were performed once. NMR experiments with the AlbAS–albicidin
complex were performed ﬁve times and a representative spectrum is shown in e. NMR experiments using albicidin derivatives were conducted once
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(Supplementary Figure 11B). The binding tunnel is decorated by
residues of all helices, except for the N-terminal helix α1 (Fig. 5a),
and exhibits a predominantly hydrophobic inner surface. The
building blocks A, B, and C of albicidin are surrounded by the
NTD of AlbAS, whereas building blocks D, E, and F are enclosed
by the CTD. The high-salt crystallization conditions reﬂect the
hydrophobic character of the interaction, which is mediated by
several hydrophobic residues pointing into the tunnel, e.g., F16,
W27, W56, L60, L71, T88, I95, L130, W133, P134, W162, and
W195 (an overview of all interacting residues is given in
Supplementary Figure 13). Five out of eight Trp side chains
(W27, W56, W133, W162, and W195) line the inner surface of
the tunnel. Residues F16, W27, W133, and W162 are π-stacked to
the aromatic building blocks A, E, and F of albicidin. Besides
strong hydrophobic interactions, a salt bridge between the
carboxylate moiety of albicidin and R181 of the CTD might play
an important role for the orientation and ﬁxation of the ligand in
the tunnel (Fig. 5d). Furthermore, several hydrogen bonds
contribute to the binding of albicidin. For example, pMBA-6
(building block F) establishes two hydrogen bonds to Y169 and
Q205 of the CTD (Fig. 5d), while N24 and H78 of the NTD
hydrogen-bond to the hydroxyl and carbonyl moiety of MCA-1
(building block A), respectively (Fig. 5e). Owing to its rigid
scaffold with a single α-amino acid, albicidin adopts a V-shaped
conformation with the Cα atom of L-Cya-3 at the center and the
building blocks A-B-C and D-E-F forming the two arms that span
c
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AlbAS + compound 5
AlbAS + compound 7
AlbAS + compound 4
Fig. 4 Determination of binding afﬁnities by monitoring quenching of ﬂuorescence emission of AlbAS. a Fluorescence quenching of AlbAS (200 nM; λexc=
280 nm) with increasing albicidin concentrations. b Nonlinear regression (Eq. (2), see Methods section) of ﬂuorescence quenching data yielding a Kd of
5.6 ± 0.2 nM and a Hill coefﬁcient, n, of 3.0 ± 0.5 for the interaction of albicidin with AlbAS (20 nM). c Nonlinear regression of the quenching data yielded
Kd values of 3.4 ± 0.2 and 0.6 ± 0.1 µM for the interaction of albicidin with the dissected domains AlbASNTD (100 nM) and AlbASCTD (100 nM),
respectively. d AlbAS (20 nM) titrated with compound 4 did not lead to signiﬁcant quenching of the ﬂuorescence emission signal. e Titration of AlbAS (20
nM) with compound 5 yielded a Kd of 55.5 ± 3.6 nM (Eq. (2), see Methods section). f Titration of AlbAS (20 nM) with compound 7 yielded a Kd of 14.0
± 2.9 nM (Eq. (3), see Methods section). Representative binding curves are shown for two independent experiments each. Errors are given as s.d
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Fig. 5 Structure of the AlbAS–albicidin complex and key residues of AlbAS for albicidin binding. a AlbAS is shown in cartoon representation with the NTD
(α1-α6) in blue and the CTD (α1′-α6′) in cyan. The elongated helix α6 connecting both domains is highlighted in orange. Albicidin is shown in ball-and-stick
representation (yellow) and pervades both domains of AlbAS. b Superposition of the NTD and CTD of AlbAS. α-helical elements are labeled (a prime
indicates assignment to the CTD). The protruding helix α1 of the NTD is predicted to be part of a longer α-helical linker region of AlbAL, which connects the
HTH motif and the drug-binding region of the protein. c Superposition of the AlbAS–albicidin complex (ligand not shown) and TipAS (PDB 2MBZ)27 bound
to promothiocin A (ball-and-stick representation, carbon magenta). A region that is unfolded in isolated TipAS and forms an α-helical lid (α6-α9) after drug
binding is colored in white. Helices present in the unbound form of TipAS are drawn in dark gray. d Interactions of the AlbAS CTD with albicidin portion D-
E-F. e Interactions of the AlbAS NTD with albicidin portion A-B-C. Residues of the NTD, the CTD, and albicidin are colored in blue, cyan, and yellow,
respectively, with oxygens in red and nitrogens in blue. Hydrogen bonds and ionic interactions are indicated by dashed lines
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an angle of about 130°. Importantly, the side chain of N75 of
AlbAS forms two hydrogen bonds with the amide proton and the
carbonyl oxygen of the central L-Cya-3 (Φ and Ψ values of 66.0°
and −128.7°), thereby stabilizing this speciﬁc conformer of
albicidin. The cyanomethylene side chain of L-Cya-3 is oriented
outwards the binding tunnel approaching helices α6 and α1′.
Interestingly, the amide proton of pABA-4 is pointing at the triple
bond of the nitrile moiety with a distance of about 1.4 Å.
Besides the mainly hydrophobic character of the interaction
between AlbAS and albicidin, we propose that N75, R181, and
Q205 are important residues for recognition of albicidin. Based
on the crystal structure we generated the triple variant AlbASM
with amino-acid substitutions N75A, R181A, and Q205A
(Supplementary Figure 4A). Employing the agar diffusion assay
as a ﬁrst line of evidence, AlbASM was indeed not capable of
efﬁciently suppressing the antibacterial activity of albicidin
(Fig. 2c), albeit binding was not fully impeded (Supplementary
Figure 14).
AlbAS tolerates structural variations of albicidin. The above-
described interaction between AlbAS and albicidin raised further
questions on the tolerance of AlbAS toward structural variations
of albicidin and thus the possible design of albicidin analogs,
which could escape arrest by AlbAS. Based on previous SAR
studies, we were equipped with a number of synthetic albicidin
derivatives and substructures thereof8,9. We employed the agar
diffusion assay with E. coli and 1H-15N HSQC experiments in
order to monitor the ability of AlbAS to bind albicidin analogs
(Supplementary Figure 14 and 15).
From our library of albicidin-derived compounds we chose
seven derivatives (compounds 1–7) as well as the TipAS-speciﬁc
ligand thiostrepton A as a control substance (Fig. 1b). These
albicidin derivatives comprised variations of building blocks A
and C, which otherwise stabilize the AlbAS–albicidin complex
through hydrogen bonds to N24 and H78 (building block A),
N75 (L-Cya-3, building block C), as well as π–π stacking and
hydrophobic interactions (building block A) to W27 of AlbAS. In
compound 1, a ﬂuorine atom replaced the phenolic hydroxyl
group of the coumaric acid (building block A), thus eliminating
hydrogen bond capabilities to N24. The agar diffusion assay
showed that the presence of AlbAS abolished the antibacterial
activity of compound 1 (Supplementary Figure 15). Moreover, the
HSQC signal pattern clearly indicated strong binding by AlbAS
similar to that of albicidin (Supplementary Figure 16).
Compound 2 bore two structural modiﬁcations: (i) it was
shorter than albicidin due to a substitution of coumaric acid by a
para-hydroxy benzoic acid moiety; and (ii) L-Cya-3 was
substituted by the sterically more demanding L-Thr with H-
bond donor and acceptor capabilities. Despite the expectedly
missing hydrogen bond to residue N24 and the variation in the
side chain of L-Cya-3 (building block C), the agar diffusion assay
indeed conﬁrmed binding of the strongly antibacterial compound
2 (Supplementary Figure 15). Accordingly, we observed the
characteristic HSQC signal pattern as in the case of albicidin
binding to AlbAS (Supplementary Figure 14 and 16). Apparently,
both structural modiﬁcations (building blocks A and C) had no
signiﬁcant inﬂuence on binding by AlbAS.
In order to assess the importance of the only stereocenter in
albicidin for binding to AlbAS, we also tested the antibacterially
active enantiomer of albicidin4 bearing D-Cya-3 (compound 3).
Remarkably, AlbAS was still able to bind compound 3
(Supplementary Figure 14) and thus to prohibit its antibacterial
effects (Supplementary Figure 15).
Finally, we tested truncated albicidin derivatives (compounds
4, 5, and 6) to evaluate binding contributions from the NTD and
CTD (Fig. 1b). Compound 4 only consisted of the building blocks
A and B, and therefore addressed binding contributions from the
NTD of AlbAS. On the contrary, compound 5 comprised only the
C-terminal building blocks D, E, and F, and was thought to
potentially accommodate in the CTD of AlbAS. Ultimately,
compound 6 was devoid of building blocks A and F and was thus
hypothesized to miss essential interactions with residues N24,
W27, W162, Y169, R181, and Q205 in the NTD and CTD. The
truncated albicidin variants 4, 5, and 6 did not display
antibacterial activity (Supplementary Figure 15), however, the
change in the NMR signal pattern clearly demonstrated
interaction between AlbAS and the respective derivatives
(Supplementary Figure 14). Notably, while compounds 5 and 6
again caused spectra in the slow-exchange regime (strong
binding), compound 4 showed a gradual chemical shift change
typical for fast-exchange systems (weak binding, Fig. 4d).
Fluorescence quenching experiments with AlbAS and compound
5 resulted in a Kd of 55.5 ± 3.6 nM (Fig. 4e). Compound 4 had no
consistent effect on ﬂuorescence emission spectra of AlbAS
suggesting a very low binding afﬁnity (Fig. 4d). Taken together,
these results underline the importance of the CTD as a ﬁxation
point for albicidin.
Facing the high structural similarities between albicidin and the
anti-Gram-negative compounds cystobactamid31 and coralmy-
cin32, we tested binding capabilities of an albicidin derivative
(compound 7)33 with cystobactamid-like features (Fig. 1b). The
pattern of NMR reporter signals of AlbAS clearly pointed to a
strong binding of compound 7 in the nanomolar Kd range. Our
ﬂuorescence quenching experiments revealed a Kd of 14.0 ± 2.9
nM for compound 7 (Fig. 4f), which is similar to the binding
afﬁnity of AlbAS toward albicidin (5.6 ± 0.2 nM), however, no
cooperative behavior was observed. Analysis of the agar diffusion
assay showed that AlbAS is able to neutralize the antibacterial
effects of compound 7, albeit with decreased efﬁciency (Supple-
mentary Figure 15). Finally, thiostrepton A was devoid of any
binding afﬁnity toward AlbAS (Supplementary Figure 15 and
Supplementary Figure 14).
Discussion
AlbA has been reported as a binding protein conferring resistance
against the potent antibiotic albicidin17,19,20. Previous studies
already mentioned a single high-afﬁnity binding site for albicidin
in AlbAS20,34, and an α-helical structure19, but they lacked both
the knowledge of the chemical structure of albicidin and the high-
resolution structure of AlbAS. Our antibacterial tests using an
in vitro agar diffusion assay combined with biophysical binding
studies via CD, NMR, and ﬂuorescence spectroscopy underscore
the high binding afﬁnity of AlbAS and AlbAL toward albicidin
(Kd of 5.6 ± 0.2 and 7.4 ± 0.9 nM, respectively) and other deri-
vatives. The sensitivity of ﬂuorescence quenching experiments
was essential for the determination of such a low Kd value.
However, as we were restricted to minimum protein concentra-
tions of 20 nM, the determined Kd values could still represent
upper boundaries. Therefore, the previously reported Kd of 64
nM34 is at least one order of magnitude to high. Surprisingly,
quenching of AlbAS emission by albicidin proved to be highly
efﬁcient (100% quenching) possibly reﬂecting the network of
tryptophans in the binding tunnel, in particular in that of the
CTD (Fig. 5c).
Competition experiments with the DNA gyrase construct
GyrBA59 and albicidin (Supplementary Figure 9D and E)
demonstrated the strong binding afﬁnity of AlbAS and its ability
to protect the molecular target from inhibition. In light of pre-
viously determined IC50 values of 40 nM for DNA gyrase, we
suggest that AlbA may either be more abundant in the cell than
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DNA gyrase and/or exhibit superior association rates kon to
efﬁciently capture albicidin after cell entry.
The crystal structure of the drug-binding domain AlbAS
revealed a tandem architecture with the NTD and CTD repre-
senting structural repeats of each other that are connected by the
extended helix α6 of the NTD (Fig. 5a). Intriguingly, nature has
adapted to the elongated and fairly rigid scaffold of albicidin by
combining two TipAS-type folding units to fully enclose the
highly potent toxin. Albicidin is thus clamped between the NTD
and CTD and stabilized predominantly by hydrophobic and π–π
stacking interactions (Fig. 5d, e, Supplementary Figure 11A and
B). Based on our structural data, we can exclude the previously
suggested direct involvement of residue H125 in albicidin bind-
ing20, since this residue is located in helix α1′ and oriented
toward the protein exterior (Supplementary Figure 17). Several
hydrogen bonds, and in particular the salt bridge between the
carboxylic acid of albicidin and R181 of AlbAS, most likely confer
ligand selectivity. We assume that R181 is relevant to orient
albicidin in the binding cleft by anchoring the carboxylic acid of
pMBA-6 (building block F) in the CTD.
Attempts to crystallize AlbAS in the absence of albicidin did
not succeed. According to this, the increase in observable signals
in 1H-15N HSQC spectra of AlbAS upon albicidin binding sug-
gests that free AlbAS displays inherent protein dynamics on the
micro-to-millisecond timescale. Based on the repeat structure of
AlbAS with few direct contacts between the repeat units even in
the albicidin-bound state, we hypothesize that albicidin may ﬁx
the otherwise ﬂexible relative orientation of the NTD and CTD.
In addition, dynamics within the binding tunnel in the absence of
albicidin may also account for some of these observations, as only
three out of eight expected HSQC signals for Trp side chains were
detected with good signal-to-noise ratio (Supplementary Figure 6
and 16). Ligand-induced stabilization has also been observed for
the structurally related drug-binding protein TipAS16, for which
binding of thiopeptides induces an otherwise non-observable α-
helical lid to pack onto the ligand (Fig. 5c)27. In contrast, how-
ever, the comparison of AlbAS/AlbAL and the AlbAS/
AlbAL–albicidin complexes by CD spectroscopy showed that the
α-helical content was virtually independent of ligand binding
(Fig. 3a and Supplementary Figure 5B). The dynamic nature of
the vacant protein suggests a possible binding mechanism: AlbAS
exploits its inherent structural plasticity in order to clamp the
elongated and rather rigid albicidin molecule in a buried tunnel of
about 33 Å in length that is built from both repeat units (Sup-
plementary Figure 18). The observed positive cooperativity with
Hill coefﬁcients n of 2.0–3.0 is in agreement with a binding
process that includes recruitment of albicidin to one domain
favoring subsequent association to the neighboring domain. Such
a cooperative binding behavior has been also observed for the
MerR protein BmrR35. The strong binding of albicidin conse-
quently leads to a well-deﬁned NTD-CTD arrangement in AlbAS
causing an increase in thermal stability, ΔTm, of about 15 °C.
Our concept of ligand-mediated domain-domain bridging is
supported by binding effects caused by albicidin fragments:
despite strong binding to AlbAS (Kd of 55.5 ± 3.6 nM), the C-
terminal segment of albicidin (compound 5) did not cause the
appearance of additional resonances in the HSQC spectrum of
AlbAS, and neither did compounds 4 and 6 (Supplementary
Figure 14). This observation demonstrates that the fragments
were not capable of efﬁciently stabilizing the NTD-CTD
arrangement (Supplementary Figure 18), while all tested full-
length analogs of albicidin did (Supplementary Figure 14).
Intriguingly, the full-length cystobactamid-type analog (com-
pound 7) was not able to stabilize AlbAS to a similar extent as
albicidin (Fig. 3d, g). Despite binding with low nanomolar afﬁnity
(Kd of 14.0 ± 2.9 nM) similar to albicidin, compound 7 showed no
positive cooperativity (Fig. 4f). Moreover, compound 7 provoked
chemical shift patterns in HSQC spectra of AlbAS reminiscent of
those of the C-terminal albicidin fragment (compound 5). We
could not achieve crystallization of the AlbAS–compound 7
complex either. Taken together, these observations clearly sup-
port that cystobactamid is mainly bound to the CTD of AlbAS
without properly bridging the NTD and CTD. As AlbAS can
tolerate a shortened building block A (para-hydroxy benzoic acid
in compound 2, see Supplementary Figure 14), the steric demand
of β-methoxy-L-Asn and its anticipated effect on the backbone
conformation in building block C appears to hinder the stabili-
zation of both domains. In a previous study, we identiﬁed various
naturally occurring derivatives of albicidin, amongst them a less
active variant with a β-methoxy-L-Asn residue33. Hence, this
modiﬁcation may represent a natural mechanism against AlbA-
mediated transcriptional regulation.
Truncated AlbAS variants composed of a single domain were
not sufﬁcient to properly arrest albicidin: AlbASNTD and
AlbASCTD were not able to neutralize albicidin in the agar dif-
fusion assay (Fig. 2b) due to their much weaker binding afﬁnities.
Fluorescence quenching experiments yielded Kd values for albi-
cidin binding of 3.4 ± 0.2 µM (NTD) and 0.6 ± 0.1 µM (CTD),
respectively, indicating that recruitment of albicidin to AlbAS
may be guided by the CTD. We propose that a binding pathway
from the CTD toward the NTD of AlbAS would ensure that
albicidin is ﬁrst fully trapped in AlbAS before the binding signal is
relayed to the N-terminal HTH domain of full-length AlbAL to
induce DNA binding. The high afﬁnity of AlbAS toward the C-
terminal fragment of albicidin (compound 5) further supports the
idea of the CTD as an initial anchoring point (Supplementary
Figure 18).
Interestingly, when comparing AlbAS with AlbBS only key
residues W162, Y169, and R181 of AlbAS are conserved in AlbBS
(Supplementary Figure 2B). These residues interact with pMBA-6
(building block F) of albicidin indicating that AlbBS might
recognize this C-terminal pMBA-motif, but that its cognate
ligand might otherwise deviate from the albicidin structure. In
light of the reduced afﬁnity of AlbAS toward the cystobactamid-
type compound 7, the missing binding cooperativity and the
reduced stabilization effect we propose that AlbAS has been
evolutionarily optimized to capture albicidin rather than the
related cystobactamids or coralmycins31,32. Whether AlbBS
represents a corresponding cystobactamid- or coralmycin-
binding protein will be the subject of future investigations.
Sequence alignments and secondary structure predictions
demonstrate the widespread occurrence of AlbAS homologs with
tandem architecture among several ESKAPE pathogens (Supple-
mentary Figure 3). These homologs are sequentially different
(≤58% difference to AlbAL) but are predicted to adopt a similar
α-helical repeat structure in which key residues important for
albicidin binding are conserved. The AlbA-mediated sequestra-
tion of albicidin might thus operate in clinically relevant patho-
gens, which showed resistance against albicidin (MIC value ≥64
µg mL−1). However, at this point it is unclear to which extent
albicidin capture by AlbA homologs contributes to the overall
antibacterial resistance in vivo, as several resistance strategies will
act in concert. Likewise, it will be necessary to identify full-length
AlbAL and the truncated AlbAS species in vivo, and to quantify
their cellular abundances.
Given the ligand promiscuity of the TipAS system27,36, and
other MerR effector-binding domains (i.e., BmrR)37, we studied
whether AlbAS can accept structurally different albicidin deri-
vatives by using an in vitro agar diffusion assay and an HSQC-
based binding assay. While the former assay only provided
information on the AlbAS-mediated neutralization of anti-
bacterial derivatives, the NMR experiments gave a direct read-out
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on the binding capabilities of AlbAS. The synthetic albicidin
derivatives submitted to these assays probed steric as well as
electronic requirements for effective binding by AlbAS.
As discussed above, the albicidin fragments could not efﬁ-
ciently ﬁx the two domains of AlbAS. This observation supports
the suggested clamping mechanism, for which albicidin deriva-
tives are required that can span the entire binding tunnel, thus
connecting the NTD and CTD (Supplementary Figure 18).
Structural variations at the N terminus of albicidin (building
block A), like the withdrawal of hydrogen bond capabilities
(compound 1) or the replacement of methyl coumaric acid with
para-hydroxy benzoic acid (compound 2) had no signiﬁcant
effect on AlbAS binding. In addition, a polar L-Thr instead of L-
Cya-3 (compound 2) was similarly tolerated by AlbAS (Supple-
mentary Figure 16). Remarkably, as shown for the albicidin
enantiomer (compound 3), inversion of the only stereocenter of
the molecule was not detrimental to recognition by AlbAS. The
agar diffusion assay clearly demonstrated the neutralizing effect of
AlbAS toward compound 3 and the characteristic signal patterns
in the HSQC spectra conﬁrmed a binding mode equivalent to that
of albicidin (Supplementary Figure 16). AlbAS binding of the
enantiomeric compound 3 might be explained based on the
orientation of albicidin in the crystal structure: the side chain of L-
Cya-3 points out of the binding pocket toward the protein surface
(Fig. 5a). The surrounding helices α1′, α4, and α6 would leave
sufﬁcient space for D-Cya-3 while preserving the overall binding
mode of albicidin. These ﬁndings show that the rather ﬂexible
AlbAS tolerates structural modiﬁcations of the oligo-aromatic
scaffold of albicidin.
A connection between AlbA and transcriptional regulator
proteins has previously been suggested by Weng et al.19 and could
be corroborated by our bioinformatics analysis (Supplementary
Figure 1). The structural homology to TipAS (Fig. 5c) suggests
that AlbAS is a member of the MerR-type transcriptional reg-
ulator family. The N-terminal HTH DNA-binding domain
requires future studies on the mechanism of transcriptional reg-
ulation by AlbAL. This includes questions on how signal trans-
duction within AlbAL is triggered by albicidin binding to its drug-
binding domain. Our studies on the full-length protein AlbAL
(Supplementary Figure 5) already indicated that the binding mode
of albicidin in AlbAS is equivalent to that in AlbAL (Supple-
mentary Figure 5A and F). A major difference between the two
systems is the dimerization of AlbAL crucial for DNA binding, in
contrast to the monomeric state of AlbAS (Supplementary Fig-
ure 7). In both cases, quaternary structure is albicidin-independent
illustrating that the binding stimulus is relayed from the NTD
toward the HTH motif to trigger promoter binding and in con-
sequence the expression of, e.g., MDR transporters21.
For the TipAL system it has been suggested that the (partially)
unfolded N-terminal region in unbound TipAS becomes folded
upon thiopeptide binding. Formation of this α-helical lid (α6-α9)
stabilizes the ligand and forwards the signal to the HTH DNA-
binding domain27. Owing to the different ligand-binding sites
and the different structural organizations of the TipAS and AlbAS
N termini (Fig. 5c), the mechanisms of intramolecular signal
transduction might differ for these two systems and need to be
further investigated. Importantly, the proposed binding pathway
proceeding from the CTD toward the NTD and ﬁnally the HTH
motif may ensure a cooperative coupling between the drug-
binding stimulus and DNA binding only when the cognate ligand
is fully arrested. To avoid AlbA-mediated resistance, two cases
therefore need to be differentiated in drug development of albi-
cidin, i.e., analogs that (i) are not prone to AlbAS capture at all or
(ii) are still bound by AlbAS but do not trigger transcriptional
regulation (Supplementary Figure 18). Future studies are envi-
saged to answer these questions.
In summary, our ﬁndings contribute to a general under-
standing of resistance strategies of bacteria against antibiotics.
The knowledge on AlbA and homologous members of this
widespread class of binding proteins will be generally useful for
future antibiotic-development efforts. Depending on their phar-
macophores, potent antibiotics could be designed such that they
either completely bypass capture or that they do not trigger
regulative effects on a cellular level despite being partially arrested
by AlbA-like drug-binding proteins.
Methods
Bioinformatics. The BLAST38 was used for a protein sequence homology search
and preparation of a phylogenetic tree39. Secondary structure predictions were
performed with PSIPRED and PROMALS3D40,41.
Cloning. A codon-optimized synthetic albAS (Supplementary Table 2) coding
region (Thermo Scientiﬁc GmbH, Schwerte, Germany) was cloned into an AmpR-
pMAT vector system, using NdeI and NotI restriction enzyme sites. The plasmid
was ampliﬁed in E. coli BL21 DH5α, extracted, double digested with NdeI and NotI,
and the released fragment was cloned into expression vector pET-28a (+) for
production of AlbAS bearing an N-terminal, TEV-cleavable His6-tag. Codon-
optimized synthetic albAL (Supplementary Table 2, Thermo Scientiﬁc GmbH) was
cloned by Gibson cloning42 into an expression vector pET-28a (+) for production
of AlbAL bearing an N-terminal, TEV-cleavable His6-tag.
The amino-acid substitutions (N75A, R181A, and Q205A) in the triple variant
AlbASM as well as the substitutions for the Trp-to-Phe variants of AlbAS (W5F,
W27F, W56F, W110F, W133F, W162F, W195F, and W203F) were inserted by
Gibson assembly cloning42. To this end, one primer pair (Supplementary Table 3)
was designed to carry the point mutation in the respective base triplet and to
amplify one-half of the gene. The other primer pair ampliﬁes the remaining vector
and possesses a 16 bp overhang matching to the 3′-end of the other linear
construct. Both constructs were ligated with Taq DNA ligase (New England Biolabs
GmbH, Frankfurt am Main, Germany) after puriﬁcation with gel electrophoresis by
incubation in the Gibson mixture. The mutated plasmid was then transformed into
E. coli DH5α cells by heat shock. Transformants were selected on Luria Bertani
(LB)-agar plates supplemented with 50 μg mL−1 kanamycin and conﬁrmed later by
sequencing of the gene.
The AlbASNTD and AlbASCTD constructs were cloned using the Gibson
assembly method42 with the primer pairs listed in Supplementary Table 3. The
boundaries for the truncated AlbAS variants (AlbASNTD M1-E132 and AlbASCTD
D128-E221) were based on bioinformatic analysis before solving the AlbAS crystal
structure.
Protein synthesis and puriﬁcation of AlbAS and AlbAL. All genes including
albAS, albAL, albASM, albASNTD, albASCTD, and the Trp-to-Phe mutants were
expressed in E. coli BL21-Gold (DE3) strain (Merck Millipore, Darmstadt, Ger-
many) with the T7 promoter expression system pET-28a (+) bearing an N-
terminal TEV-cleavable His6-tag in LB medium. The expression was induced with
0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG, Biomol, Hamburg, Ger-
many) and the cells were further incubated at 18 °C, 180 rpm for 18 h. For isotope
labeling, cells were grown in M9-minimal medium containing 15N ammonium
chloride (1 g L−1), 13C6 D-glucose (3 g L−1), and/or deuterium oxide. Cells were
harvested by centrifugation and the resuspended cell pellet (50 mM Tris-HCl, 500
mM NaCl, and 5% glycerin, pH 7.5) was lysed by one passage through a high-
pressure cell disrupter TS 0.75 KW (Constant Systems Limited, Königswinter,
Germany) at 18 000 psi and incubated with DNAse (3 U per mL lysate). Subse-
quently, cell lysates were centrifuged at 55 000 × g for 30 min to separate the cell
debris from soluble protein. The crude supernatant was ﬁltered through a 45 µm
ﬁlter membrane before loading on the puriﬁcation column. AlbAS/AlbAL pur-
iﬁcation was performed by afﬁnity chromatography on an ÄKTApuriﬁer system
(GE Healthcare, Munich, Germany) by making use of the N-terminal His6-tag
binding to a Nickel His-Trap Fast Flow Crude 1 mL column (GE Healthcare). The
washing buffer consisted of 50 mM Tris-HCl and 300 mM NaCl at pH 7.5. Then
AlbAS/AlbAL was eluted with a buffer containing 50 mM Tris-HCl, 300 mM NaCl,
and 500 mM imidazole. To remove imidazole the protein fractions were diluted
with the washing buffer and concentrated in centrifugal ﬁlter units (Merck,
Darmstadt, Germany) with a cutoff of 10 000 nominal molecular weight limit.
Cleavage of the His-tag was performed for 2 h at room temperature and 16 h at 4 °
C with the addition of 100 μM of puriﬁed TEV protease. The separation of the
protein from the cleaved His-tag was performed by a second puriﬁcation step
employing the Nickel His-Trap column as described before. Desalting and buffer
exchange was accomplished by size-exclusion chromatography on a Superdex High
Load 16/60 75 column (GE Healthcare) in the ﬁnal buffer used for NMR studies
(sodium hydrogen phosphate 50 mM and 100 mM NaCl, pH 6.8). The collected
fractions were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and the protein concentration was determined on a nano-photometer P330
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05551-4
10 NATURE COMMUNICATIONS |  (2018) 9:3095 | DOI: 10.1038/s41467-018-05551-4 | www.nature.com/naturecommunications
(Implen, Munich, Germany). For long-time storage, the aliquots (0.5 mL) of pro-
tein samples were shock-frozen in liquid nitrogen and stored at −80 °C.
Selenomethionine-labeled protein was produced in 500 mL M9-minimal
medium with addition of 25 mg selenomethionine, 50 mg lysine, 50 mg threonine,
50 mg phenylalanine, 25 mg leucine, 25 mg isoleucine, and 25 mg valine shortly
bevor induction with 0.2 mM IPTG (at OD600 of 0.7–0.8). Cells were incubated at
18 °C, 180 rpm for 20 h43. Puriﬁcation was carried out as described above for wild-
type AlbAS. The ﬁnal buffer contained 50 mM Tris (pH 7.5), 100 mM NaCl, and 4
mM dithiothreitol (DTT).
Preparation of GyrBA59. The E. coli fusion protein GyrBA59, combining the full-
length GyrB and a C-terminally truncated GyrA segment (59 kDa), was cloned into
pET-28a (+) by restriction/ligation (forward and reverse primers are listed in
Supplementary Table 3) using the restriction enzyme sites NdeI and XhoI.
GyrBA59 was expressed in E. coli BL21 DE3 over 18 h at 18 °C and 250 rpm using
auto induction medium. The cells were harvested and resuspended in buffer 1A
(20 mM Tris, 150 mM NaCl, 10 mM imidazole, 10% glycerol, 2 mM DTT, EDTA-
free protease inhibitor cocktail (cOmplete, Roche), and DNase 2 U per mL lysate,
pH 8.0). After cell lysis with 14 000 psi using a high-pressure cell disrupter TS 0.75
KW (Constant Systems Limited, Königswinter, Germany) the lysate was cen-
trifuged at 50 000 × g at 4 °C for 30 min and subsequently incubated with DNAse
(2 U per mL lysate) for another 30 min at 4 °C. The protein was puriﬁed in four
steps as follows: (1) cell lysate was loaded onto a His-Trap HP column and washed
back to baseline in buffer 1B (20 mM Tris, 500 mM NaCl, 10 mM imidazole, 10%
glycerol, 2 mM DTT, and EDTA-free protease inhibitor cocktail, pH 8.0) before
being eluted with a gradient from buffer 1B into buffer 1C (20 mM Tris, 300 mM
NaCl, 300 mM imidazole, 10% glycerol, 2 mM DTT, and EDTA-free protease
inhibitor cocktail, pH 8.0) over 15 column volumes. (2) Pooled fractions were
equilibrated against buffer 1A and digested with TEV protease (1 mg per 10 mg of
protein) overnight at 4 °C to cleave the N-terminal 6x His-tag. The mixture was
loaded onto a His-Trap HP column and the tag cleavage protein was recovered
from the ﬂow through in buffer 2A (20 mM Tris, 10 mM NaCl, 5% glycerol, 2 mM
DTT, and EDTA-free protease inhibitor cocktail, pH 8.0). (3) The protein fractions
were equilibrated against buffer 2A and loaded onto a Heparin Sepharose column
to be eluted with a gradient from buffer 2A into buffer 2B (20 mM Tris, 1 M NaCl,
10% glycerol, 2 mM DTT, and EDTA-free protease inhibitor cocktail, pH 8.0) over
15 column volumes. (4) Fractions from step 3 were concentrated using a 100 kDa
cutoff ﬁlter unit, before being loaded onto a Superdex 200 HiLoad 16/60 column
(GE Healthcare) equilibrated and eluted in buffer 3A (20 mM Tris, 100 mM KCl, 1
mM DTT, and 10% glycerol, pH 8.0). The collected fractions were analyzed by
SDS-PAGE and the protein concentration was determined on a nano-photometer
P330 (Implen, Munich, Germany). Post size-exclusion fractions were pooled,
concentrated, and stored at −80 °C.
DNA cleavage assay. E. coli DNA gyrase cleavage assays were performed by
incubating 250 ng of supercoiled pBR322 plasmid DNA (Inspiralis, Norwich, UK)
with 25 nM of GyrBA59 protein in 20 µL reactions containing 35 mM Tris-HCl
(pH 8.0), 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM spermidine, 1.4 mM
ATP, 6.5% (w/v) glycerol, and 0.1 mgmL−1 bovine serum albumin in the presence
or absence of various concentrations of albicidin (ﬁnal concentration of 5%
dimethyl sulfoxide (DMSO), incubation at 37 °C for 30 min). Linearized DNA was
released by further incubation with 0.2% (w/v) SDS and 0.1 mgmL−1 proteinase K
(Promega, Madison, USA) at 37 °C for 30 min. The reaction was stopped by
addition of 20 µL of reaction stop buffer (STEB buffer) (40% (w/v) sucrose, 100
mM Tris-HCl (pH 8.0), 10 mM EDTA, and 0.5 mgmL−1 Bromophenol Blue) and
precipitation using 30 µL of chloroform/isoamyl alcohol 24:1 (v:v). Samples were
analyzed by electrophoresis in 1% w/v agarose gel containing 0.5 mg mL−1 ethi-
dium bromide followed by photography under ultraviolet illumination.
MIC assay. The MIC assay was performed by Antiinfectives Intelligence GmbH
(Rheinbach, Germany) using internationally standardized protocols and employing
clinical isolates of K. oxytoca, K. pneumoniae, R. ornithologica, P. aeruginosa, A.
baumannii and E. cloacae.
Chemical synthesis. Synthesis protocols and analytical data have been recently
described for albicidin9, compound 18, compounds 3, 5, and 614 as well as com-
pounds 4 and 733. The coupling of the N-terminal building block and the global
deprotection of compound 2 are described in the Supplementary Methods part 1.
Thiostrepton A was purchased from Merck (Darmstadt, Germany).
Agar diffusion assay. To verify the neutralizing ability of AlbAS, AlbAL, AlbASM,
AlbASCTD, or AlbASNTD against different compounds, agar diffusion assays with
the respective compounds were performed. An overnight culture of E. coli DH5α
was diluted to an OD600 of 0.05 with 0.75% LB-agar. The protein-albicidin reaction
mixture consisted of a 1:1 mixture of 40 μM albicidin (or derivatives) with 40 μM
protein (either AlbAS or its variants AlbAL, AlbASM, AlbASNTD, and AlbASCTD).
The mixture was incubated for 20 min at room temperature in the dark. Reaction
mixtures of 30 μL were transferred in triplicates of 2 mm holes on the inoculated
agar plate. The plates were evaluated concerning growth-inhibition zone after
incubation for 18 h at 37 °C.
CD spectroscopy. For determination of the melting temperature and information
on protein-ligand stability, CD measurements were performed on a J-815 CD
spectrometer (Jasco, Groß-Umstadt, Germany). Protein samples (2.0 mM for
AlbAS and 0.2 mM for AlbAL) were saturated with 1.5-fold albicidin and diluted to
a protein concentration of 20 μM in order to ensure a ﬁnal DMSO content of only
0.05% for AlbAS and 0.5% for AlbAL. A volume of 250 μL of the reaction mixture
was transferred into a quartz cuvette with 1 mm path length. Six far-UV spectra
were accumulated in a wavelength range of 195–300 nm (203–300 nm for AlbAL)
at three different temperatures (10, 21, and 90 °C) with a scanning speed of 50 nm s
−1. For evaluation of the spectra the measured buffer blank (50 mM sodium
hydrogen phosphate and 100 mM NaCl, pH 6.8) was subtracted from the averaged
spectra. The temperature curves were recorded from 10–90 °C in 0.5 °C min−1
steps while monitoring the ellipticity at 215 nm (218 nm for ALbAL). The resulting
values were recalculated into molar ellipticity [Θ]MRW with consideration of con-
centration, path length, number of amino acids, and molecular weight of the
sample. For visualization purposes, the temperature curves of AlbAS–albicidin and
AlbAS–compound 5 in Fig. 3b, c were scaled to that of AlbAS using scaling factors
of 1.175 and 1.091, respectively. The melting temperatures of AlbAS,
AlbAS–albicidin, AlbAS–compound 5, AlbAS–compound 7, AlbAL, and
AlbAL–albicidin were determined by nonlinear regression of the measured data
using Eq. (1). In case of AlbAS–albicidin a biphasic unfolding curve was observed,
which we ascribed to the two-domain arrangement. The Tm was thus determined
by ﬁtting the second transition representing the stabilized domain/species. In all
other cases, the protein unfolding curves appeared as monophasic.














with Θ being the measured ellipticity, ΔHv:Hm denoting the van’t Hoff enthalpy at
the transition point, ΘN and mN as well as ΘU and mU deﬁning the pre-transition
and post-transition phase.
NMR spectroscopy. For binding studies with albicidin and its derivatives, each
ligand was dissolved in 100% d6-DMSO and added to 15N-labeled AlbAS or 2H,
15N-labeled AlbAL in 50 mM sodium hydrogen phosphate (pH 6.8), 150 mM NaCl
buffer (usually 0.24 mM AlbAS or AlbAL in 85% buffer, 5% d6-DMSO, and 10%
D2O) yielding a 1.5-fold excess of the ligand. After incubation for 20 min at room
temperature in the dark, the sample was centrifuged at 20 000 × g for 3 min and the
supernatant was transferred to a 5 mm NMR tube. The AlbAS blank sample
(Supplementary Figure 14) was measured in 100% buffer without addition of
ligands and DMSO. Spectra were recorded on a Bruker Avance III 700MHz NMR
spectrometer (Bruker BioSpin, Rheinstetten, Germany) with a TXI probe head.
Standard Bruker pulse sequences were used. 2D 1H-15N HSQC spectra were
recorded at 298 K with acquisition times of 90 and 22 ms for the 1H and 15N
dimension, respectively. The experiments were accumulated with ≥16 scans
depending on protein sample concentration. 2D 1H-15N TROSY spectra were
accumulated with 256 scans and acquisition times of 90 and 22 ms for the 1H and
15N dimension, respectively. Several AlbAS–albicidin samples were measured with
the same result and a representative spectrum is given for the ﬁgures in the main
manuscript and the SI. NMR experiments with AlbAS and albicidin analogs were
conducted once with accumulation of ≥16 scans depending on protein con-
centration. For alignment of HSQC and TROSY spectra, the TROSY spectrum was
corrected by 1/2 1JNH in both dimensions.
AlbAS–albicidin titration experiments were performed by means of 1H-15N
HSQC experiments. Samples were prepared similarly as in the method described
above: spectra were recorded at 303 K for AlbAS in buffer (50 mM sodium
hydrogen phosphate and 150 mM NaCl, pH 6.8) at different protein-albicidin
ratios. Albicidin was added to a 0.8 mM 15N-labeled AlbAS sample to the following
ﬁnal protein-albicidin ratios: 0.1, 0.2, 0.5, 0.8, and 1. During each titration step, the
DMSO concentration was increased and reached a ﬁnal concentration of 7.3% (v/
v). The experiment was conducted once with accumulation of 16 scans for each
titration step. The spectra were recorded with acquisition times of 90 and 20 ms in
the direct 1H and indirect 15N dimension, respectively.
For the competition experiment with the DNA gyrase construct GyrBA59, 1.7
mM ATP was incubated with 3.4 mM MgCl2 for 10 min. Subsequently, 30 µM
GyrBA59 and 3 µg supercoiled pBR322 plasmid DNA (Inspiralis) were added and
incubated for another 10 min. Finally, 30 µM 15N-labeled AlbAS were added to the
mixture followed by 30 µM albicidin (10% D2O and 5% DMSO ﬁnal
concentration). Owing to the low protein concentrations (to achieve a 1:1 ratio of
gyrase and AlbAS), a 1H-15N band-selective optimized ﬂip-angle short-transient
heteronuclear multiple quantum coherence (SOFAST HMQC)44 experiment was
performed. The 1H-15N SOFAST HMQC was recorded with 2048 scans and with
acquisition times of 45 and 38 ms for the 1H and 15N dimensions, respectively.
Measurements were performed at 303.2 K. The control experiment was performed
under the same conditions but without the addition of MgCl2, ATP, pBR322
plasmid DNA, and GyrBA59.
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For preliminary resonance assignments, three-dimensional HNCA and HNCO
experiments were performed employing 13C, 15N-AlbAS (0.8 mM) saturated with
albicidin. All NMR data were processed and analyzed with Bruker TopSpin 3.1
Software and SPARKY45.
Size-exclusion chromatography with multi-angle light scattering. SEC-MALS
experiments were performed at 18 °C in buffer containing 50 mM Tris (pH 7.5),
100 mM NaCl, and 0.02% NaN3. A sample of 225 µg of AlbAS or AlbAL (with and
without saturating amounts of albicidin) were loaded onto Superdex 75 or
Superdex 200 increase 10/300 columns (GE Healthcare) that were coupled to a
miniDAWN TREOS three-angle light-scattering detector (Wyatt Technology) in
combination with a RefractoMax520 refractive index detector. For calculation of
the molecular mass, protein concentrations were determined from the differential
refractive index with a speciﬁc refractive index increment (dn/dc) of 0.185 mL g−1.
Data were analyzed with the ASTRA 6.1.4.25 software (Wyatt Technology).
Fluorescence assay. Fluorescence quenching measurements were performed by
monitoring tryptophan ﬂuorescence of AlbAS (20 nM), AlbAL (20 nM),
AlbASNTD, and AlbASCTD (100 nM) on a FluoroMax 2 spectrometer from Horiba
(Potsdam, Germany). The excitation wavelength was set to λexc= 280 nm. Emis-
sion spectra were recorded from λem= 290–450 nm with a scanning speed of 1 nm
s−1 and an integration time of 1 s. The excitation and emission slit widths were set
to 8 and 4 nm, respectively. Proteins were solved in 50 mM sodium phosphate
buffer with 150 mM NaCl and 0.01% DMSO at pH 6.8. All measurements were
performed twice and the standard deviation is given for the Kd and the Hill factor
n. Data evaluation was performed by integration of the emission band (318–410
nm for AlbAS, 316–412 nm for AlbAL, and 319–390 nm for AlbASNTD and
AlbASCTD) for every titration step. The area under the curve (AUC) of the buffer
blank (buffer with 0.01% DMSO) was subtracted from the measured titration data.
The quenching factor was determined by subtraction of AUCs for each titration
step from the AUC of the protein in the absence of ligand. For determination of the





where [L], n, and Bmax denote the total ligand concentration, the Hill coefﬁcient,
and the maximum binding capacity of the protein, respectively. For the determi-
nation of the Kd for AlbASNTD–albicidin and AlbASCTD–albicidin as well as for
AlbAS–compound 5, the Hill coefﬁcient was constrained to n= 1 for the nonlinear
regression as the binding curve showed no cooperativity.
For the determination of the Kd for AlbAS–compound 7 the data were ﬁtted to
Eq. (3).
Y ¼
Pt½  þ L½  þ Kdð Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




where Pt is the total protein concentration.
Crystallization. Crystals of unlabeled and selenomethionine-labeled AlbAS (1.4
mM AlbAS saturated with 2.5-fold albicidin in 50 mM Tris (pH 7.5), 100 mM
NaCl, 4 mM DTT, and 5% DMSO) were obtained by the sitting-drop vapor-
diffusion method at 18 °C with a reservoir solution composed of 0.1 M Tris/HCl
(pH 8.5) and 2.0 M ammonium sulfate. For crystallization 96-well MRC plates were
used. The volume of the reservoir solution was 80 μL and the crystallization drop
contained 0.5 μL reservoir solution and 0.5 μL protein solution. Crystals had
dimensions of 200 μm× 150 μm× 50 μm and appeared within 3 days. Crystals were
cryo-protected with a solution composed of equal volumes of mother liquor and
3.4 M sodium malonate at pH 7.0 and subsequently ﬂash-cooled in liquid nitrogen.
Structure determination and reﬁnement. Synchrotron diffraction data were
collected at the beamline 14.1 and 14.2 of the MX Joint Berlin laboratory at BESSY
(Berlin, Germany) at a wavelength of 0.97949 Å and temperature of 100 K. Dif-
fraction data were processed with XDS46. Experimental phases were determined by
single anomalous dispersion with the AUTOSOL routine in PHENIX47 using
PHASER48 and SOLVE/RESOLVE49 exploiting the selenomethionine-labeled
AlbAS (Supplementary Table 1). There were 35 heavy-atom sites in the asymmetric
unit (FOM: 0.413, BAYES-CC: 60.3). An initial model of AlbAS was built with the
program AUTOSOL in PHENIX47. All dihedral angles were found in favored
(99.8%) and allowed (0.2%) regions of the Ramachandran plot. Our structure
contains no Ramachandran plot outliers. The structure was reﬁned by maximum-
likelihood restrained reﬁnement using in PHENIX, including TLS reﬁnement50.
Model adjustment and water picking was performed with COOT51. Geometrical
restraints used in the reﬁnement of albicidin were generated by using the Grade
Web Server (http://grade.globalphasing.org) that queries the Cambridge Structural
Databank with optional quantum chemical regularization. Model quality was
evaluated with MolProbity52 and the JCSG validation server53. Secondary structure
elements were assigned with DSSP54, and ALSCRIPT55 was used for secondary
structure-based sequence alignments. Figures were prepared using PyMOL56 and
channels were calculated with CAVER57.
Data availability. The atomic coordinates and structure factor amplitudes have
been deposited in the Protein Data Bank under the accession code 6ET8. Other
data are available from the corresponding author upon reasonable request.
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